# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gwen Ifill (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML032-SYN-TD
- Date: 2016-01-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorna Achebe-Price, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Spotting, then light bleeding on and off for about three weeks, eight years after her periods stopped; no pain **S**
- She does not want a wait-and-see answer: she knows that bleeding after menopause is sometimes put down to nothing, and she wants the cause found quickly and told plainly **S**
- She wants to keep working and to decide who is told **S**

## Your goals

- Endometrial tissue diagnosis and ultrasound within one week, and a gynecologic oncology plan within three weeks of presentation. Target: 2016-01-20. Recorded outcome: Biopsy at the first visit, ultrasound in two days, result in four days, CT in eight, consultation at two weeks. **S**
- Surgical staging within four weeks of diagnosis. Target: 2016-02-24. Recorded outcome: Minimally invasive hysterectomy with sentinel node mapping and para-aortic node removal two weeks after the consultation. **S**
- Six cycles of dostarlimab with carboplatin and paclitaxel every three weeks without a delay of more than one week. Target: 2016-06-30. Recorded outcome: Six cycles on schedule; CT shows no evidence of disease. **S**
- Lynch syndrome tumor screening completed and explained before treatment starts. Target: 2016-02-24. Recorded outcome: MLH1 promoter hypermethylation found: acquired, not inherited; genetic counseling done. **S**
- Immune-related adverse events found early: TSH, liver tests, glucose and cortisol checked on schedule. Target: 2016-06-30. Recorded outcome: Hypothyroidism found on a scheduled TSH and treated without stopping dostarlimab; one missed baseline cortisol recorded and corrected. **S**
- PHQ-9 below 10 throughout treatment, with support she chooses. Target: 2016-06-30. Recorded outcome: PHQ-9 between 4 and 6. **S**

## What we agreed to do

- Gynecologic oncology consultation within two weeks to review the endometrial biopsy and ultrasound with her and plan treatment if cancer or atypical hyperplasia is found. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol 2026;148(1):e87-e91 (PMID 41990335) (2026) **S**
- Any bleeding after menopause is evaluated: speculum and bimanual examination, office endometrial biopsy at the first visit, and transvaginal ultrasound within the week, both done rather than relying on endometrial thickness alone; blood count and A1c; results by telephone within days, not at a routine visit. Guideline: Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol 2026;148(1):e87-e91 (PMID 41990335) (2026); Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol 2018;131(5):e124-e129 (PMID 29683909) (2018); Clarke MA, et al. Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA Oncol 2022;8(6):895-903 (PMID 35511145) (2022); Doll KM, et al. Assessment of Prediagnostic Experiences of Black Women With Endometrial Cancer in the United States. JAMA Netw Open 2020;3(5):e204954 (PMID 32412636) (2020) **S**
- Staging and molecular classification: CT of the chest, abdomen and pelvis; mismatch repair immunohistochemistry and p53 on the biopsy, with MLH1 promoter methylation testing for MLH1 loss and POLE sequencing on the surgical specimen; FIGO 2013 stage with the molecular class recorded. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383-394 (PMID 37337978) (2023); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026) **S**
- Robotic-assisted total laparoscopic hysterectomy with removal of both tubes and ovaries, pelvic washings, sentinel lymph node mapping with indocyanine green, and removal of the enlarged pelvic and para-aortic nodes. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026) **S**
- Lynch syndrome screening of the tumor for every endometrial cancer, with genetic counseling; germline testing if mismatch repair loss is not explained by MLH1 promoter methylation, and cascade testing offered to blood relatives only if a germline variant is found. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol 2014;124(5):1042-1054 (PMID 25437740) (2014); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026) **S**
- Dostarlimab 500 mg with carboplatin (AUC 5) and paclitaxel 175 mg/m2 every three weeks for six cycles, then dostarlimab 1000 mg every six weeks for up to three years, for mismatch repair deficient stage IIIC2 disease; hepatitis B, hepatitis C and HIV screening first; three-drug antiemetic prevention; blood counts, kidney function and magnesium before each cycle; TSH, free T4, liver tests, glucose and morning cortisol at baseline and before each cycle; neuropathy checks at each visit. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023); JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026) **S**
- Immune-related hypothyroidism: levothyroxine with TSH and free T4 every six weeks, continuing dostarlimab. Guideline: JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026) **S**
- Survivorship: examination with a pelvic examination every three months for two years, CT of the chest, abdomen and pelvis every six months for three years, no routine vaginal cytology and no CA-125 (normal at diagnosis), teaching on symptoms of recurrence, lymphedema checks, sexual health, weight, activity, blood pressure, lipid and glucose care, distress screening, and age-appropriate screening for other cancers. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026) **S**
- Distress and depression screening at each visit, plain explanations, written information, and support she chooses; she decides who receives each note. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**

## Follow-up

- 2016-01-05: Three weeks of postmenopausal bleeding in a woman of 60: examination, office endometrial biopsy, transvaginal ultrasound, and gynecologic oncology review booked **S**
- 2016-01-20: Biopsy result: endometrial cancer; staging CT, gynecologic oncology consultation, Lynch syndrome tumor screening, and preparation for surgery **S**
- 2016-02-24: Review three weeks after surgical staging: final pathology and molecular class, genetic counseling, and the first cycle of dostarlimab with carboplatin and paclitaxel **S**
- 2016-04-28: Midpoint of combination treatment: blood counts, immune-related adverse event checks, neuropathy, and mood **S**
- 2016-06-30: End of combination treatment: response CT, immune-related hypothyroidism, the first maintenance dostarlimab dose, and the survivorship plan **S**
- 2016-08-11: Periodic adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
